0001567619-22-012414.txt : 20220607 0001567619-22-012414.hdr.sgml : 20220607 20220607121951 ACCESSION NUMBER: 0001567619-22-012414 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220607 DATE AS OF CHANGE: 20220607 EFFECTIVENESS DATE: 20220607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mytide Therapeutics, Inc. CENTRAL INDEX KEY: 0001905245 IRS NUMBER: 831051996 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-430375 FILM NUMBER: 221000444 BUSINESS ADDRESS: STREET 1: 451 D STREET SUITE 707 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: (207) 659-4206 MAIL ADDRESS: STREET 1: 451 D STREET SUITE 707 CITY: BOSTON STATE: MA ZIP: 02210 D/A 1 primary_doc.xml X0708 D/A LIVE 0001905245 Mytide Therapeutics, Inc. 451 D STREET SUITE 707 BOSTON MA MASSACHUSETTS 02210 (207) 659-4206 DELAWARE None None Corporation true 2017 Dale Thomas 451 D Street, Suite 707 Boston MA MASSACHUSETTS 02210 Executive Officer Director Promoter Mr. Thomas is the President of the Issuer. Jason Norris 451 D Street, Suite 707 Boston MA MASSACHUSETTS 02210 Executive Officer Director Promoter Mr. Norris is the Treasurer and Secretary of the Issuer. Errik Anderson 451 D Street, Suite 707 Boston MA MASSACHUSETTS 02210 Director Biotechnology Decline to Disclose 06b true 0001567619-22-001406 2021-12-30 false true true Series A Preferred Stock false 0 7067713 7067713 0 false 23 0 0 0 false Mytide Therapeutics, Inc. /s/ Dale Thomas Dale Thomas President of the Issuer 2022-06-07